NEW ORLEANS, April 3, 2011 /PRNewswire/ — A pooled analysis of
the SPIRIT II, III, IV and COMPARE trials presented today further
reinforces the positive clinical performance of Abbott’s (NYSE:
ABT) market-leading XIENCE V® Everolimus Eluting
Coronary Stent System. As part of the analysis of all four trials,
two-year results on the safety and efficacy of XIENCE V compared to
TAXUS® Liberte® and TAXUS®
Express2™ Paclitaxel-Eluting Coronary Stent Systems (TAXUS)
were presented at the American College of Cardiology’s (ACC) 60th
Annual Scientific Session and i2 Summit 2011 in New Orleans.
In a presentation given by Dean J. Kereiakes, M.D., medical
director of The Christ Hospital Heart and Vascular Center in
Cincinnati, Ohio, predictors of artery re-blockage, cardiac death
or heart attack were evaluated out to two years in nearly 7,000
patients from the SPIRIT II, III, IV and COMPARE clinical trials.
The data demonstrated that use of XIENCE V resulted in
significantly lower clinical event rates following a stent
procedure. In the pooled analysis, XIENCE V demonstrated a 36
percent reduction in the risk of major adverse cardiac events
(MACE) compared to TAXUS (7.3 percent for XIENCE V versus 11.1
percent for TAXUS, p-value<0.001). MACE is an important
composite clinical measure of safety and efficacy outcomes for
patients, defined as cardiac death, heart attack (myocardial
infarction or MI), or retreatment of a lesion (ischemia-driven
target lesion revascularization, or ID-TLR).
“XIENCE V consistently demonstrated low adverse cardiac event
rates in trial after trial,” said Dr. Kereiakes. “The SPIRIT II,
III, IV, and COMPARE pooled analysis suggests that XIENCE V reduced
the occurrence of adverse events compared to patients treated with
the TAXUS stent. The low event rates demonstrated by XIENCE V in
these trials are esp
‘/>”/>
